cellular matrix (ECM) are mediated primarily by the integrin family of adhesion receptors. These are heterodimeric transmembrane glycoproteins, consisting of ␣ and ␤ subunits, possessing both adhesive and signaling properties. Ligand and signaling specificity is conferred by their heterodimeric composition. 1 Endothelial cells have been shown to express a variety of integrins including ␣v␤3, a receptor for fibronectin, vitronectin, osteospontin, von Willebrand factor, laminin, and collagen. 2, 3 The ability of integrins to act as a bridge between the extracellular and intracellular environments allows them to mediate ECM-induced changes in vascular tone, permeability, and vessel remodeling, and, as such, they have been depicted as key receptors for detecting and responding to vascular injury after damage to the ECM. 4 There is mounting evidence that interactions between integrins and the ECM are important in regulating many aspects of vascular biology. For example, we have shown that ␣5-integrin and fibronectin are essential for early blood vessel development. 5 Several studies demonstrate that endothelial cells must be anchored to the matrix for survival, migration, and proliferation. 6 -8 Further-more, changes in the matrix milieu that activate different integrins can regulate the levels of fibroblast growth factor and vascular endothelial growth factor (VEGF) receptors on endothelial cells. 9 VEGF, also known as vascular permeability factor, 10 is unique among growth factors in that it is an important regulator of angiogenesis and a potent vasodilator capable of increasing vascular permeability. 11, 12 The most widely studied form of VEGF belongs to the VEGF-A family and is a 38-kDa homodimeric peptide (VEGF 165 in humans;VEGF 164 in mice is henceforth referred to as VEGF-A) belonging to the larger family of VEGFs. 13 The biological actions of VEGF are mediated through 2 tyrosine receptor kinases, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1), and a more recently identified receptor, neuropilin-1, which is believed to be a coreceptor for VEGF acting in concert with VEGFR-2. 14 We have shown previously that VEGF-induced angiogenesis is enhanced in mice that are deficient in ␤3-integrin and that this response is associated with increased levels of Flk-1. 15 In this study we have addressed the role of ␤3integrin in regulating VEGF-A-mediated vascular permeability. By examining the leakage of Evans blue dye from the vascular system, we show that blood vessels in ␤3-null mice are more sensitive to VEGF-A-induced permeability. By administering either cells or animals with the monoclonal antibody DC101 directed against Flk-1, 16 we show, for the first time to our knowledge, that this enhanced response is mediated by the elevated Flk-1 on ␤3-null endothelial cells. We see no morphological defects in ␤3-null vessels when compared with wild-type controls, nor is baseline permeability altered, demonstrating that the absence of ␤3-integrin does not affect normal blood vessel structure or integrity. These results indicate that ␤3-integrin regulates levels of Flk-1 and thereby influences VEGF-A-mediated permeability.
Methods

Animals
␤3-integrindeficient 17 and wild-type control mice were 8 to 12 weeks of age. Lectin visualization of blood vessels was performed on mice from a 129sv genetic background, whereas all other studies were performed on mice from a C57/BL6 background. All animals were used in accord with United Kingdom Home Office regulations.
Reagents
For a detailed list of reagent sources, please see http://atvb. ahajournals.org
Miles Assays
Please see http://atvb.ahajournals.org for a detailed protocol of these methods.
Lectin Staining
Morphometric Measurements of Vessels
Vessel area density, vessel number density, and vessel diameters were measured in lectin-stained whole mounts as described by Thurston et al. 18 
Transmission Electron Microscopy
Ultrastructural analysis of microvessels was from saline-injected skin (as described for the Miles assay). Fifteen minutes after injection, skin surrounding the sites of injection was dissected and processed for electron microscopy.
Western Blotting, Flow Cytometry, and Immunofluorescence
Western blots, flow cytometry, and immunofluorescence were performed as described by Reynolds et al. 15 
In Vitro Permeability Assay
Transwell permeability assays were performed on monolayers of mouse endothelial cells as described by Wójciak-Stothard. 19 VEGF 164 (30 ng/mL) in the presence or absence of DC101 (20 g/mL) was added to both the upper and lower chambers of the transwell concomitant with fluorescein isothiocyanate (FITC)dextran (1 mg/mL) addition to the upper chamber. Samples were collected and assayed 30 minutes after VEGF stimulation.
In Vivo DC101 Treatments
Pre-experimental treatments were two 0.8-mg intraperitoneal injections of DC101 (100 L in phosphate-buffered saline [PBS]) or either an equivalent concentration of a rat IgG isotyope control (in PBS) or an equivalent volume of PBS only, on days 0 and 3. VEGF 164 intradermal injections and Miles assays were performed on day 6, as described.
Statistical Analysis
Data are presented as meansϮSEM. Significant differences between means were evaluated by unpaired Student t test. PϽ0.05 was considered significant.
Results
VEGF-A-Induced Vascular Permeability Is Enhanced in ␤3-Integrin-Deficient Mice
To analyze the role of VEGF-A-mediated permeability, we used the Miles assay 20 to measure vascular leakage in the skin of ␤3-integrindeficient and wild-type control mice. Mice were injected intravenously with Evans blue dye followed by intradermal injections of either 400 ng VEGF-A or vehicle (saline) alone. Spectrophotometric analysis of specimens from 8-mm biopsy punches performed around the sites of injection (using the point of injection as the center of the punch) showed that within 15 minutes after VEGF-A treatment, blood vessels in ␤3-null mice were Ϸ2.5-fold more permeable than vessels in wild-type mice ( Figure 1A ). At this suboptimal concentration of VEGF-A, vessels in wild-type animals exhibited minimal dye leakage when compared with vehicle-only controls. Moreover, a higher (600 ng) dose of VEGF-A was required to induce a significant degree of plasma leakage in wild-type mice, indicating that ␤3-null mice are more responsive to VEGF-A.
The extravasated Evans blue measured in this type of experiment is caused by both vessel permeability and vessel dilation. Although we cannot distinguish between the two, vessel dilation usually accounts for Ͻ0.01% of leakage in the type of assay described. 21, 22 
Baseline Permeability and Inflammation-Induced Permeability Are not Affected by ␤3-Integrin Deficiency
Because VEGF-A-mediated vessel permeability was enhanced in ␤3-null mice, we then asked if ␤3-integrindeficiency affected baseline vessel permeability. To address this, we first examined circulating VEGF levels in wild-type and ␤3-null mice. Enzyme-linked immunosorbent assay results measuring serum levels of VEGF are presented in Figure 1B . No significant differences in VEGF levels were observed between wild-type and ␤3-null mice, indicating that in a young, healthy population of mice, circulating levels of VEGF are not affected by the absence of ␤3-integrin. In addition, no evidence of edema was observed in the ␤3-null mice (data not shown).
We next compared vascular leakage in ear skin under baseline conditions. Mice were injected intravenously with Evans blue dye followed by topical application of mineral oil (a noninflammatory agent used as the vehicle in subsequent inflammatory assays) to the epidermis of the ear. Spectrophotometric analysis of dissected ears showed that within the 30-minute time frame of the experiment, no significant difference was observed in dye leakage between wild-type and ␤3-null mice ( Figure 1C ).
We next investigated vascular leakage in ear skin in response to mustard oil, an inflammatory agent that induces acute plasma leakage in the skin. 23 Mice were injected intravenously with Evans blue dye, followed by topical application of mustard oil to the epidermis of the ear, as described (for the baseline assays). Spectrophotometric analysis of dissected ears showed that 30 minutes after Evans blue administration, mustard oil treatment induced Ϸ2.5-fold in-crease in dye leakage (when compared with baseline levels) in vessels from both wild-type and ␤3-null mice; no difference was observed when comparing levels of leaked dye between the 2 genotypes ( Figure 1D ). Although the data presented are from samples collected 30 minutes after initial mustard oil treatment, we have not seen any differences in vascular leakage between ␤3-null and wild-type vessels at either earlier (15 minutes) or later (60 minutes) time points (data not shown). Taken together, these data indicate that baseline permeability and inflammation induced permeability of vessels in ␤3-null mice is equivalent to that of vessels in wild-type mice.
Blood Vessels in the Skin of ␤3-Null Mice Are Morphologically Normal
The vessels in the skin of ␤3-null mice appeared normal. The skin was not reddened and we saw no overt signs of edema (data not shown). We have shown previously that there are no differences between wild-type and ␤3-null mice in the number of platelet and endothelial cell adhesion molecule (PECAM)-positive vessels in normal back skin. 15 The architecture of the microvasculature was examined in wholemount preparations of ear skin from wild-type and ␤3-null mice in which vessels were visualized with biotin-labeled BS-1 lectin, which binds to the luminal surface of endothelial cells. 24 The vessels throughout the skin of the ear appeared normal (Figure 2A) . A quantitative analysis revealed no differences in vessel area density (reflecting the overall number, length, and size of vessels per unit area), vessel number density (reflecting the total number of vessels traversing the ear per unit area, independent of vessel size), or in the average diameter of microvessels ( Figure 2B ).
The amount of plasma leakage in inflammation depends, at least in part, on the number and size of sites for leakage in the endothelium. 25 These leakage sites expose the underlying endothelial basement membrane and can therefore be visualized in whole-mount preparations with ricin lectin, which binds more avidly to components of the basement membrane than the endothelium. 26 In untreated vessels, rhodaminelabeled ricin lectin binding to the endothelial luminal surface was weak and uniform in both genotypes (data not shown). In mustard oil-treated ears, ricin lectin bound very strongly to focal sites of exposed basement membrane in vessels presumed to be venules based on vessel diameter and various models of acute inflammation. 27 The degree of ricin lectin binding was comparable in both genotypes. We did not see any differences in the number (data not shown) or location of exposed basement membrane sites in wild-type versus ␤3null vessels ( Figure 2C) .
Analysis by transmission electron microscopy confirmed an intact microvascular network in the skin of untreated ␤3-null mice. ␤3-null vessels, including capillaries, were unaltered in size and showed normal pericyte recruitment and cell-cell contacts between endothelial cells and supporting cells ( Figure 3A and data not shown).
Endothelial cell-to-cell junctions are complex structures formed by different adhesive molecules. 28 Endothelial cells possess adherens junctions and tight junctions similar to those described in epithelial cells. Adherens junctions are ubiqui- tous along the vascular tree and are formed by transmembrane proteins belonging to the cadherin superfamily. Endothelial cells express a cell-specific cadherin known as vascular endothelial cell cadherin (VECAD). Tight junctions comprise 3 types of transmembrane proteins, occludins, claudins and junctional adhesion molecule. In addition, other adhesive proteins, such as PECAM, and endoglin are concentrated at intercellular contacts in the endothelium. As a measure of the molecular architecture of junctions in wildtype and ␤3-null endothelial cells, we performed Western blot analysis for occludin ( Figure 3B ) on lung endothelial cells derived from wild-type and ␤3-null animals; flow cytometry for PECAM and VECAD ( Figure 3C ) on lung endothelial cells derived from wild-type and ␤3-null animals; and immunofluorescence ( Figure 3D ) on both frozen skin sections and isolated lung endothelial cells from both genotypes. Wild-type and ␤3-null endothelial cells showed equivalent expression of all 3 cell-cell adhesion molecules, sug- gesting that adherens junctions, tight junctions, and other cell adhesions are normal in ␤3-null cells.
Inhibition of Flk-1 Function Abrogates VEGF-A-Induced Permeability in ␤3-Null Mice
Given that no differences in either vessel structure or junctional protein levels were observed when comparing wildtype and ␤3-null blood vessels, but that VEGF-A-mediated permeability and Flk-1 levels ( Figure 4A ) were significantly elevated in ␤3-null mice, we asked if elevated Flk-1 levels were directly responsible for the enhanced VEGF-A-mediated vessel permeability response. To address this in vitro, we cultured monolayers of wild-type and ␤3-null endothelial cells in transwell chambers and measured the flux of FITCdextran across the monolayers in response to treatment with either VEGF-A alone or VEGF-A in combination with the neutralizing anti-Flk-1 antibody DC101 16 (Figure 4B ). To address this in vivo, we administered DC101 to wild-type and ␤3-null mice and measured VEGF-A-induced vessel leakage using the Miles assay ( Figure 4C ). Both analyses revealed that by inhibiting the function of Flk-1, VEGF-A-induced permeability was completely abolished in ␤3-null endothelium. These results indicate that increased levels of Flk-1 in ␤3-null mice are directly responsible for an increased sensitivity to VEGF-A-mediated blood vessel permeability.
Discussion
The establishment and maintenance of a vascular network is critical for normal embryological development and has significant implications for pathological processes such as wound healing and tumorgenesis. Numerous investigations have demonstrated that interactions between integrins and the ECM are important to these processes. 2,6,29 -32 A major focus of these studies has been on the roles played by ␣v␤3-integrin and ␣v␤5-integrin in angiogenesis. [33] [34] [35] [36] [37] During angiogenesis, ␣v␤3 expression is upregulated. 38 Furthermore, its expression is linked to cell migration, invasion, and cell survival. 38 -40 Given these collective data, it is surprising that genetic ablation of ␣v-integrin elicits only minor vessel defects. 41 Although most ␣v-deficient mice die soon after birth, a complex embryonic vascular network develops. In addition, ␤3-deficient mice are viable and fertile and appear to produce a vascular network without obvious defects. 17, 42 A detailed morphological examination of skin blood vessels in ␤3-null mice, presented here, indicates that the vasculature is intact and indistinguishable from that of wild-type mice, reinforcing the conclusion that ␤3-integrin is not necessary for establishing a normal vasculature.
Endothelial cells attach to the ECM to form a semipermeable barrier restricting movement of solutes across the vascular wall. Evidence that integrins are involved in maintaining this barrier comes from studies showing that treating endothelial monolayers or isolated coronary venules with RGD peptides (small molecules that disrupt interactions between integrins and the ECM) increase their permeability. [43] [44] [45] The fact that the increased permeability in these in vitro studies is prevented by the addition of soluble fibronectin or vitronectin suggests that interactions between integrins and the ECM influence vessel permeability. From the data we present here, however, we are able to conclude that ␤3integrin is not essential for maintaining an intact and functional endothelial barrier. These data are as follows: (1) baseline vessel permeability is not altered in ␤3-deficient mice; (2) a molecular comparison of the endothelial cell-tocell contacts between the 2 genotypes revealed no differences in the expression of PECAM, VECAD, or occludin; and (3) wild-type and ␤3-null blood vessels respond equally to mustard oil-induced plasma leakage. Collectively, these data indicate that ␤3-integrin is not necessary for maintaining baseline integrity of the endothelial barrier.
In marked contrast to the lack of an apparent phenotype in vessel structure and baseline integrity, we see an increase in the sensitivity of ␤3-null vessels to subthreshold doses of VEGF-A treatment. Changes in matrix composition and integrin activation can influence levels of, and signaling through, VEGF and fibroblast growth factor receptors on cultured microvascular endothelial cells. 9, 46, 47 We show that the absence of ␤3-integrin is associated with an increase in the levels of Flk-1 expressed on endothelial cells and, for the first time to our knowledge, that this increase in Flk-1 leads to an increased sensitivity to VEGF-A-mediated permeability in vitro and in vivo. Previously, we were able to draw correlations between only elevated Flk-1 levels and enhanced VEGF-mediated angiogenesis. 15 With respect to permeability, however, we show that by inhibiting signaling through Flk-1, we abolish the enhanced VEGF-A response seen in ␤3-null vessels. This demonstrates that the increased Flk-1 is functional and is entirely responsible for the elevated sensitivity to VEGF-A-induced permeability.
Conventional treatment of vascular leakage is rather aspecific and includes treatments such as the administration of glucocorticoids or nonsteroidal inflammatory drugs and antihistaminergic compounds. Recently, VEGF antagonists 48 and VEGF receptor inhibitors 49 have been used with some success in treating the increased vessel leakiness associated with macular degeneration, diabetic retinopathy, and ischemiareperfusion injury. By genetically ablating ␤3-integrin function, we have altered blood vessel sensitivity to VEGF-Ainduced plasma leakage, indicating that integrins might be additional useful targets for clinically manipulating vessel permeability.
Antagonists of ␣v␤3 and ␣v␤5, some of which are in clinical trials, 50 have been shown to block angiogenesis, suggesting that these integrins are required for angiogenesis. However, we have shown that ␤3-integrindeficient mice support enhanced pathological angiogenesis. 15 The data we present here and in our previous studies suggest that ␤3integrin acts as a transdominant inhibitor of VEGF-mediated vascular functions, with its presence being enough to downregulate levels of Flk-1. We have previously demonstrated that the reintroduction of ␤3-integrin into null endothelial cells restores Flk-1 levels to those seen in wild-type cells, 15 suggesting that ␤3-integrin can regulate Flk-1 expression. Hence, eliminating ␤3-integrin interactions with the ECM might alter the response of endothelial cells to VEGF. The antagonist of ␣v␤3-integrin, LM609, has been shown to enhance vascular permeability. 51 If inhibition of ␣v␤3integrin has the potential of elevating Flk-1 levels in endothelial cells, both angiogenesis and permeability of tumor vessels could be increased, especially if, as many are, 52 the tumor is a source of VEGF production. This might prove detrimental to the treatment of the tumor. We do not question the efficacy of ␣v␤3 antagonists as potentially useful therapeutic agents, but our results suggest we need a more thorough understanding of the interactions between integrins and other molecules that are involved in regulating angiogenesis and permeability.
Many vascular disorders are accompanied by alterations in production and/or degradation of ECM components and by alterations in integrin expression. 4 Because of this, integrins are obvious therapeutic targets for treating a host of vascular diseases such as hypertension, diabetes mellitus, and restenosis. [53] [54] [55] [56] This idea is exciting and should be explored, but with the thought in mind that manipulating integrin expression might lead to an increase in growth factor receptor levels expressed by endothelial cells. As we show here, genetically ablating ␤3-integrin function elevates Flk-1 levels on endothelial cells. This has the potential of affecting vessel growth and vessel permeability, both of which have important implications for current and future therapeutics. Vessel leakiness, for example, is known to contribute to the abnormal microenvironment of tumors and can affect tumor growth, metastasis, and therapeutic drug delivery. 57 As long as we exercise caution, though, integrins may provide us with useful targets for treating a range of vascular disorders.
